All In Biotech

Drug Trial Radar · NCT00110448

Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial

Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,539 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,539

Actual

Start

Dec 2002

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
Kumamoto UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan.

Conditions

  • Coronary Disease
  • Arteriosclerosis
  • Diabetes Mellitus, Type 2

Interventions

  • AspirinDrug

    Aspirin 81 mg or 100 mg per day

  • No aspirinDrug

    No aspirin use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardiovascular eventsTime frame: five years (median)
  2. Cerebral vascular eventsTime frame: five years (median)
  3. Aortic and peripheral vascular events, which needs internal medicine and/or surgical medical treatmentTime frame: five years (median)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

    Kumamoto, Kumamoto, Japan

  • First Department of Internal Medicine, Nara Medical University

    Kashihara, Nara, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.